Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials – investor.lilly.com

1. Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials  investor.lilly.com
2. Orforglipron for maintenance of body weight reduction: the…

Continue Reading

News Source: news.google.com